Cart
sales@molnova.com
Home -
Products -
Immunology/Inflammation -
Complement System -
C3a 70-77 2TFA(63555-63-5(free base))
C3a 70-77 2TFA(63555-63-5(free base))
CAS No. ——
C3a 70-77 2TFA(63555-63-5(free base))( Complement 3a (70-77) )
Catalog No. M22774 CAS No. ——
C3a 70-77 2TFA is an octapeptide corresponding to the COOH terminus of C3a.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 205 | In Stock |
|
| 10MG | 342 | In Stock |
|
| 25MG | 572 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameC3a 70-77 2TFA(63555-63-5(free base))
-
NoteResearch use only, not for human use.
-
Brief DescriptionC3a 70-77 2TFA is an octapeptide corresponding to the COOH terminus of C3a.
-
DescriptionC3a 70-77 2TFA is an octapeptide corresponding to the COOH terminus of C3a.
-
In Vitro——
-
In Vivo——
-
SynonymsComplement 3a (70-77)
-
PathwayImmunology/Inflammation
-
TargetComplement System
-
RecptorComplement system
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number——
-
Formula Weight823.94
-
Molecular FormulaC35H61N13O10
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOC(=O)C(F)(F)F.OC(=O)C(F)(F)F.CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CO)NC(=O)[C@H](C)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Payan, D. G . Modulation of human lymphocyte function by C3a and C3a(70-77)[J]. Journal of Experimental Medicine, 1982, 156(3):756-765.
molnova catalog
related products
-
ADH-503
ADH-503 is a potent agonist of the integrin CD11b to mitigate myeloid cell immunosuppression.
-
C3a 70-77
C3a 70-77 is an octapeptide corresponding to the COOH terminus of C3a.
-
Vesencumab
Vesencumab (MNRP-1685A) is an IG1 antibody targeting NRP-1 with anti-angiogenic and anti-tumor activity that reduces the number of globules formed by the SUM159 and Hs578T cell lines. Vesencumab inhibits EGFR and PDGFRα activation and can be used to study solid tumors.
